Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
Blood Adv
.
2023 Apr 25;7(8):1572-1576.
doi: 10.1182/bloodadvances.2022007868.
Authors
Evandro D Bezerra
1
,
Madiha Iqbal
2
,
Javier Munoz
3
,
Arushi Khurana
1
,
Yucai Wang
1
,
Matthew J Maurer
4
,
Radhika Bansal
1
,
Matthew A Hathcock
1
,
Nora Bennani
1
,
Hemant S Murthy
2
,
Allison C Rosenthal
3
,
Jonas Paludo
1
,
Jose C Villasboas
1
,
Patrick B Johnston
1
,
Thomas M Habermann
1
,
Stephen M Ansell
1
,
Januario E Castro
3
,
Thomas E Witzig
1
,
Mohamed A Kharfan-Dabaja
2
,
Grzegorz S Nowakowski
1
,
Yi Lin
1
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN.
2
Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL.
3
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
4
Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
PMID:
36219588
PMCID:
PMC10139860
DOI:
10.1182/bloodadvances.2022007868
No abstract available
MeSH terms
B-Lymphocytes
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, B-Cell* / therapy
Lymphoma, Non-Hodgkin* / therapy